VALORISATION AND OPTIMIZATION OF NOVEL FIRST-IN CLASS SUCCINATE-DEPLETING THERAPIES

SUCCIPRO is a spin-off company from Pere Virgili Health Institute and Rovira Virgili University.

It is an early-stage drug development company focused on therapies able to modulate the succinate-SUCNR1 pathway, which have strong potential on many inflammatory and metabolic disorders.

Currently, the company is developing SUCZYME, a novel first-in-class oral enzyme therapy able to deplete succinate that has Crohn's Disease as a first indication.

SUCCIPRO will lead the development until the end of Clinical Phase 2a, when the asset will be licensed to a bigger pharma company.Current proposal aims to conduct critical technical and business activities with the overall goal of raising a first seed investment round.

From a technological perspective, during the project the team will advance in the development of the enzyme therapy by partnering with an innovative company expert in enzyme engineering able to improve our candidates in terms of specificity, activity and stability. Later, we will conduct in vitro and in vivo efficacy studies that will enable the designation of final lead candidate.

In parallel to the technical development, and in order to have more a more accurate vision about the European market, we aim to perform early price & reimbursement and market studies in Europe.

We will also participate in the activities organised by InvestEU and the Enterprise Europe Network and we will introduce our company into the US start-up ecosystem to expand company's innovation network and look for investment in the US.

Overall, the project will contribute to increase the TRL level of our asset, improve our competitiveness and visibility within the international biotech sector and support us in the raising of a seed investment round.